Research programme: cocaine abuse therapeutics - Molecular Insight Pharmaceuticals

Drug Profile

Research programme: cocaine abuse therapeutics - Molecular Insight Pharmaceuticals

Alternative Names: Cocaine abuse therapies research programme - Molecular Insight Pharmaceuticals; CTDP 31446

Latest Information Update: 05 Jan 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Harvard Medical School; Molecular Insight Pharmaceuticals
  • Class
  • Mechanism of Action Biogenic monoamine uptake inhibitors; Dopamine plasma membrane transport protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cocaine abuse

Most Recent Events

  • 20 Jan 2003 Preclinical trials in Cocaine abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top